In vivo reversal of doxorubicin resistance by a new tiapamil analog Ro11-2933

• Published in: The Journal of pharmacology and experimental therapeutics Vol. 264; no. 3; pp. 1299 - 1304
• Main Authors: ALAOUI-JAMALI, M. A, SCHECTER, R. L, RUSTUM, Y. M, CENTURIONI, M. G, LEHNERT, S, BATIST, G
• Format: Journal Article
• Language: English
• Published: Bethesda, MD American Society for Pharmacology and Experimental Therapeutics 01.03.1993
• Subjects: Animals; Antineoplastic agents; Biological and medical sciences; Calcium Channel Blockers - pharmacology; Cell Division - drug effects; DNA Damage; Doxorubicin - pharmacokinetics; Doxorubicin - pharmacology; Drug Resistance; Female; General aspects; Mammary Neoplasms, Experimental - pathology; Medical sciences; Pharmacology. Drug treatments; Propylamines - pharmacology; Rats; Rats, Inbred F344; Tumor Cells, Cultured - drug effects; Verapamil - pharmacology; Cell culture; Carcinoma; Calcium antagonist; Cytotoxicity; Malignant tumor; In vitro; Resistance; Mammary gland diseases; In vivo; Chemotherapy; Cell line; Treatment; Analog; Drug interaction; Mammary gland; Tumor cell; Comparative study
• ISSN: 0022-3565; 1521-0103

The effectiveness of a calcium antagonist analog Ro11-2933 to modulate doxorubicin (DOX) response in DOX-sensitive (WT) and -resistant (DOXr, 200-fold) cell lines was investigated and compared to verapamil (VP) in vitro and in vivo in rats bearing mammary carcinoma using equivalent nontoxic doses. In vitro exposure to a nontoxic concentration of Ro11-2933 (2 microM) normalizes the DOX accumulation defect observed in DOXr cells, increases DOX-induced DNA single-strand breaks and effectively sensitizes DOXr cells to DOX. Ten microM VP was required to obtain an effect equivalent to that seen with 2 microM Ro11-2933. Intravenous administration of DOX at 5 mg/kg to the rat bearing the DOXr tumors has no significant therapeutic effect on tumor growth (P > .5), whereas it was found effective in inhibiting the growth of WT tumors (P < .05). Ro11-2933 or VP administered alone has no significant effect on tumor growth as compared to a saline-treated group (P > .1). Combination of Ro11-2933 with DOX effectively inhibits DOXr tumor growth as compared to DOX alone. Combination of DOX with VP was found less effective than Ro11-2933 and the results were not statistically significant from DOX treatment alone (P > .5). Our data demonstrate that Ro11-2933 is well tolerated after i.v. administration and an effective modulator of DOX resistance in a solid tumor model.